Q3 beat strengthens credibility of GSK's execution skills
29/10/25 -"The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, the management raised its 2025 guidance. Overall, ..."
Pages
65
Language
English
Published on
29/10/25
You may also be interested by these reports :
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...
30/10/25
While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability ...
29/10/25
The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, ...
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...